Trial Search Results
Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes
The purpose of this study is to learn about the impact of continuous glucose monitoring (CGM) on families with newly diagnosed children with type 1 diabetes (T1D). The investigators hope to learn about how continuous glucose monitoring affects glycemic variables and diabetes-related distress.
Stanford is currently accepting patients for this trial.
Collaborator: University of Colorado, Denver
- Device: CGM at diagnosis of T1D
To be eligible for the study, a child must meet the following criteria:
1. Diagnosis of type 1 diabetes according to American Diabetes Association diagnostic
2. Time since diagnosis of no longer than one month
3. Age between 2 and 17 years
4. Parental consent (and assent from the child where applicable) to participate in the
5. No severe medical conditions, which in the opinion of the investigators are likely to
hinder participation in this clinical trial.
To be eligible for the study, a parent must meet the following criteria:
1. Parent or legal guardian of a child with type 1 diabetes meeting the "child" criteria
2. Age of 18.0 years or older
3. Parent comprehends written English
4. Parent understands the study protocol and signs the informed consent document
The presence of any of the following is an exclusion for the study:
1. Child has a medical disorder that in the judgment of the investigator will interfere
with completion of any aspect of the protocol (e.g., pregnancy, kidney disease,
adrenal insufficiency, skin condition that may hinder sensor application).
2. Child has a neurologic disorder that in the judgment of the investigator will affect
completion of the protocol
3. Current use of oral glucocorticoids or other medications, which in the judgment of the
investigator would be a contraindication to participation in the study
4. Child is unable to completely avoid acetaminophen for duration of study
Ages Eligible for Study
2 Years - 17 Years
Genders Eligible for Study